ARK Genomic Revolution ETF (ARKG) Fund Overview

ARK Genomic Revolution ETF (ARKG) Financial Services Profile

ARK Genomic Revolution ETF (ARKG) is an actively managed ETF targeting companies at the forefront of the genomics revolution. The fund invests across multiple sectors, both domestically and internationally, seeking long-term capital appreciation through exposure to innovative genomic technologies and advancements. It offers investors a focused approach to capitalize on the growth potential within the genomics space.

What Is the Investment Thesis for ARKG?

ARKG's investment thesis centers on the long-term growth potential of companies involved in the genomics revolution. The fund's value drivers include the increasing adoption of genomic sequencing, gene editing technologies, and personalized medicine. As of March 2026, the genomics market is projected to continue its expansion, driven by technological advancements and decreasing sequencing costs. ARKG's active management allows it to adapt to the evolving landscape, capitalizing on emerging opportunities and mitigating risks. A key metric is the fund's exposure to companies with high growth rates in revenue and earnings, reflecting their leadership in the genomics space. The fund's success depends on its ability to identify and invest in companies that are driving innovation and disrupting traditional industries. The ongoing catalysts include advancements in CRISPR technology, increased regulatory approvals for gene therapies, and the expansion of genomic applications in healthcare and agriculture. The potential risks involve regulatory hurdles, competition from other genomics companies, and market volatility.

Based on FMP financials and quantitative analysis

ARKG Key Highlights

ARKG's focus on genomics provides exposure to a high-growth sector with transformative potential.

• The fund's active management allows for dynamic portfolio adjustments to capitalize on emerging opportunities.
• ARKG invests in both domestic and foreign companies, offering diversification across geographies.
• The ETF structure provides investors with a liquid and transparent way to access the genomics market.
• ARKG's investment strategy is driven by in-depth research and analysis of companies involved in the genomics revolution.

Who Are ARKG's Competitors?

ARKG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ARKG's Key Strengths?

Focus on a high-growth sector with transformative potential.

• Active management allows for dynamic portfolio adjustments.
• Diversification across domestic and foreign companies.
• Strong brand recognition within the thematic ETF space.

What Are ARKG's Weaknesses?

High beta of 2.76 indicates higher volatility compared to the market.

• Concentrated focus on genomics may lead to sector-specific risks.
• Actively managed funds may underperform the market due to management decisions.

What Could Drive ARKG Stock Higher?

Advancements in CRISPR technology and gene editing techniques.

• Increased regulatory approvals for gene therapies and personalized medicine products.
• Expansion of genomic sequencing and bioinformatics applications in healthcare and agriculture.

What Are the Key Risks for ARKG?

Regulatory hurdles and ethical concerns surrounding gene editing and personalized medicine.

• Competition from other genomics companies and ETFs.
• Market volatility and economic downturns impacting the genomics sector.
• Technological obsolescence and disruption within the genomics sector.

What Are the Growth Opportunities for ARKG?

• Expansion of Genomic Sequencing: The market for genomic sequencing is projected to grow significantly as costs continue to decline and applications expand. ARKG can capitalize on this trend by investing in companies that are developing and commercializing new sequencing technologies. This includes companies involved in next-generation sequencing (NGS), long-read sequencing, and single-cell sequencing. The increasing adoption of genomic sequencing in clinical diagnostics, drug discovery, and personalized medicine presents a significant growth opportunity for ARKG's portfolio companies. The market size for genomic sequencing is estimated to reach $25 billion by 2028.
• Advancements in Gene Editing Technologies: Gene editing technologies, such as CRISPR-Cas9, are revolutionizing the treatment of genetic diseases. ARKG can benefit from this trend by investing in companies that are developing and commercializing gene editing therapies. This includes companies involved in ex vivo and in vivo gene editing, as well as companies developing novel delivery methods for gene editing tools. The increasing number of clinical trials for gene editing therapies and the potential for regulatory approvals present a significant growth opportunity for ARKG's portfolio companies. The gene editing market is projected to reach $10 billion by 2027.
• Growth of Personalized Medicine: Personalized medicine, which involves tailoring medical treatment to an individual's genetic makeup, is becoming increasingly prevalent. ARKG can capitalize on this trend by investing in companies that are developing and commercializing personalized medicine products and services. This includes companies involved in pharmacogenomics, companion diagnostics, and personalized cancer therapies. The increasing adoption of personalized medicine in clinical practice and the potential for improved patient outcomes present a significant growth opportunity for ARKG's portfolio companies. The personalized medicine market is estimated to reach $200 billion by 2028.
• Increasing Adoption of Bioinformatics: Bioinformatics, which involves the use of computational tools to analyze biological data, is becoming increasingly important in genomics research and development. ARKG can benefit from this trend by investing in companies that are developing and commercializing bioinformatics software and services. This includes companies involved in data analysis, data management, and data visualization. The increasing volume of genomic data and the need for efficient analysis tools present a significant growth opportunity for ARKG's portfolio companies. The bioinformatics market is projected to reach $15 billion by 2027.
• Expansion of Genomic Applications in Agriculture: Genomics is being increasingly used in agriculture to improve crop yields, enhance disease resistance, and develop more nutritious foods. ARKG can capitalize on this trend by investing in companies that are developing and commercializing genomic technologies for agricultural applications. This includes companies involved in gene editing of crops, development of genetically modified organisms (GMOs), and genomic selection of livestock. The increasing demand for sustainable and efficient agricultural practices presents a significant growth opportunity for ARKG's portfolio companies. The agricultural genomics market is estimated to reach $10 billion by 2028.

What Are ARKG's Competitive Advantages?

• First-mover advantage in focusing on the genomics revolution.
• Expertise in identifying and investing in innovative genomics companies.
• Strong brand recognition within the thematic ETF space.

What Does ARKG Do?

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) that focuses on companies involved in the genomics revolution. Launched with the goal of capturing long-term growth, ARKG invests primarily, with at least 80% of its assets, in equity securities of both domestic and foreign companies. The fund spans multiple sectors, identifying firms that are leading innovation and development in genomic sequencing, gene editing, targeted therapeutics, bioinformatics, and personalized medicine. ARKG provides investors with a vehicle to access the potential of genomic advancements, which are expected to transform healthcare, agriculture, and other industries. The fund’s investment strategy involves identifying companies that are not only currently contributing to the genomics revolution but also those poised to benefit from future advancements. By actively managing the portfolio, ARKG aims to capitalize on emerging opportunities and navigate the evolving landscape of the genomics sector. The fund’s holdings include companies of various sizes, from established players to emerging growth companies, reflecting the breadth of the genomics ecosystem. ARKG's investment approach is driven by in-depth research and analysis, seeking to identify companies with strong growth potential and competitive advantages within the genomics space. The ETF offers a diversified approach to investing in genomics, mitigating some of the risks associated with investing in individual companies. As of 2026, ARKG continues to be a prominent ETF for investors seeking exposure to the genomics revolution.

What Products and Services Does ARKG Offer?

• Invests in companies involved in genomic sequencing.
• Targets firms developing gene editing technologies.
• Focuses on companies advancing targeted therapeutics.
• Includes businesses engaged in bioinformatics.
• Invests in companies involved in personalized medicine.
• Actively manages a portfolio of domestic and foreign equity securities.
• Seeks long-term capital growth through exposure to the genomics revolution.

How Does ARKG Make Money?

• Generates revenue through management fees charged on assets under management (AUM).
• Aims to provide investors with exposure to the genomics revolution.
• Actively manages the portfolio to capitalize on emerging opportunities.

What Industry Does ARKG Operate In?

ARKG operates within the asset management industry, specifically focusing on the genomics sector. The genomics market is experiencing rapid growth, driven by technological advancements, decreasing sequencing costs, and increasing applications in healthcare, agriculture, and other industries. The competitive landscape includes other ETFs and investment funds that focus on genomics or related sectors. ARKG differentiates itself through its active management approach and its focus on companies that are driving innovation in the genomics space. The fund's success depends on its ability to identify and invest in companies with strong growth potential and competitive advantages.

Who Are ARKG's Key Customers?

• Individual investors seeking exposure to the genomics sector.
• Institutional investors looking for long-term growth opportunities.
• Financial advisors seeking to diversify client portfolios.

ARKG Financials

ARKG Latest News

ARKG Analyst Consensus

ARKG MoonshotScore

Latest ARK Genomic Revolution ETF Analysis

ARK Genomic Revolution ETF Financial Services Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources